Genelux

Performance

About Genelux

Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for cancer using the CHOICE discovery platform. The company focuses on redefining immuno-oncology across multiple indications, with Olvi-Vec as its lead candidate in a Phase 3 trial for platinum-resistant/refractory ovarian cancer. Based in the United States, Genelux emphasizes a viral immunotherapy approach that aims to enhance antitumor immune responses and overcome resistance in solid tumors.